Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 818 results for "merck co"

Dow Jones (DJIA) Today: Merck (MRK) Leads The Day Higher, Gold...

Reddit Email Reprint Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. . The Dow Jones Industrial Average ( ..., 1 hour ago

38 images for merck co

VAR India, 3 weeks ago
Sacramento Bee, 3 weeks ago
North, 3 weeks ago
KSWO, 3 weeks ago, 3 weeks ago, 1 month ago
Houston Chronicle, 3 weeks ago
Chicago Daily Herald, 3 weeks ago, 3 weeks ago
Healthcare Global, 1 month ago

Merck & Co., Inc. To Set Strong Foothold In HCV Market; Should Gilead Sciences, Inc. Be Worried?

Pharmaceutical giant Merck & Co., Inc. ( NYSE:MRK ) is on track to establish a strong foothold in the fast expanding market of HCV drugs, offering significant threat to the seemingly undisputed leader in the space, Gilead Sciences, Inc. ( ...
 Bidness Etc2 hours ago Merck (MRK) To Set Strong Foothold In Cancer Immunotherapy Market With Keytruda  Bidness Etc4 days ago

SD - Merck & Co., Inc. (0000310158) (Filer)

Document Format Files Seq Description Document Type Size 1 FORM SD - MAY 29 2015 formsd-2015_05x29.htm SD 26458 2 EXHIBIT 1.01 formsd-2015_05x29exhibit101.htm EX-1.01 38517 Complete submission text file
 SEC2 hours ago

Merck Drug Helps Colon Cancer Patients With DNA Repair Defect

A small study found that Merck & Co.'s immune system-triggering drug Keytruda shrank tumors in colon cancer patients with a specific gene flaw, showing that genetic tests may help identify those likely to benefit from immune therapy treatments. ...
 Bloomberg4 hours ago Merck & Co'smdrug cancer drug Keytruda gets a nod  Economic Times1 week ago Merck & Co's immune system-boosting cancer drug Keytruda gets a nod from European regulators  Economic Times1 week ago Merck follows Bristol with EU green light for immune cancer drug  London South East1 week ago

Stock Update (NYSE:MRK): New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck's Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Ex

[Business Wire] Merck , known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA® , the company's anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 Phase . . . → Read More: pression ...
 Vision Monday2 hours ago Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection  RCL Advisors1 day ago Merck & Co. Announces Third-Quarter 2015 Dividend  BioSpace2 days ago Merck Reports CHMP Positive Opinion For SIMPONI - Quick Facts  RTTNews.com3 days ago

The New #13 Most Shorted Dow Component: Merck

The most recent short interest data has been released by the NASDAQ for the 05/15/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by ...
 Forbes.com6 hours ago General Electric Becomes #15 Most Shorted Dow Stock, Replacing Merck  Forbes.com6 hours ago

Dow 30 Stock Roundup: GE May Divest Vehicle Management Unit, Merck's Keytruda Gets Favorable Opinion - Analyst Blog

The Dow suffered losses during a holiday shortened week, weighed down by multiple factors. Stocks started the week in the red after the dollar gained strength, which compelled investors to park funds into safe-haven assets. The Dow gained on ...
 Yahoo! Finance3 hours ago

Merck immunotherapy appears effective in head and neck cancer-study

n"May 29 A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday. A quarter ...
 Reuters4 hours ago UPDATE 1-Merck immunotherapy appears effective in head and neck cancer-study  Reuters3 hours ago MERCK : New Study Examines Barriers to Cancer Care for Women in Zambia  4 Traders1 week ago
Med India

Merck Submits NDA To FDA For Grazoprevir/Elbasvi

Merck & Co. Inc. (MRK) announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir/elbasvir (100mg/50mg), an investigational once-daily, single tablet combination therapy for the treatment of ...
 RTTNews.com21 hours ago Merck & Co files grazoprevir/ elbasvir NDA in USA  Pharma Letter8 hours ago Dosing Errors With Merck & Co. (MRK) Antibiotic Prompt FDA Warning 5/22/2015  ClinicSpace1 week ago Type 2 Diabetes Drug Januvia Does Not Increase Cardiovascular Risk in Patients  Med India4 weeks ago
Seeking Alpha

How The Big Money Cashes In On Merck

1:44 PM ET | About: Merck & Co Inc. (MRK), Includes: ABBV, AZN, BMY, GILD, PFE, RHHBY by: Pharma Doc Summary Merck's catalyst is ASCO and its star poster child is Keytruda. Merck will show off Keytruda in 5 different cancer subtypes this ...
 Seeking Alpha1 day ago Merck & Co., Amgen expand Keytruda, T-Vec collaboration to include head and neck cancer  FirstWord Pharma7 hours ago Amgen And Merck & Co. Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA (Pembrolizumab) In Patients With Head And Neck Cancer  BioSpace8 hours ago MERCK : Amgen, Merck Expand Collaboration to Head, Neck Cancer  4 Traders8 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less